State Street Corp raised its holdings in Akebia Therapeutics, Inc. (NASDAQ:AKBA) by 72.9% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 946,888 shares of the biopharmaceutical company’s stock after buying an additional 399,160 shares during the period. State Street Corp owned approximately 5.17% of Akebia Therapeutics worth $13,604,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Goldman Sachs Group Inc. boosted its position in Akebia Therapeutics by 1.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 49,277 shares of the biopharmaceutical company’s stock valued at $453,000 after buying an additional 608 shares during the period. TIAA CREF Investment Management LLC boosted its position in Akebia Therapeutics by 144.3% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 252,123 shares of the biopharmaceutical company’s stock valued at $3,623,000 after buying an additional 148,940 shares during the period. Virtu KCG Holdings LLC purchased a new position in Akebia Therapeutics in the 2nd quarter valued at approximately $607,000. DAFNA Capital Management LLC boosted its position in Akebia Therapeutics by 92.7% in the 2nd quarter. DAFNA Capital Management LLC now owns 135,738 shares of the biopharmaceutical company’s stock valued at $1,951,000 after buying an additional 65,283 shares during the period. Finally, FMR LLC boosted its position in Akebia Therapeutics by 11.3% in the 2nd quarter. FMR LLC now owns 1,036,955 shares of the biopharmaceutical company’s stock valued at $14,901,000 after buying an additional 105,100 shares during the period. 60.09% of the stock is owned by institutional investors.

Several brokerages have commented on AKBA. ValuEngine raised shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. BidaskClub raised shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 16th. HC Wainwright reaffirmed a “buy” rating and set a $24.00 price objective on shares of Akebia Therapeutics in a research report on Wednesday, August 9th. Royal Bank Of Canada began coverage on shares of Akebia Therapeutics in a research report on Thursday, September 14th. They set a “sector perform” rating and a $17.00 price objective for the company. Finally, Mizuho reaffirmed a “buy” rating and set a $24.00 price objective on shares of Akebia Therapeutics in a research report on Thursday, November 9th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $20.75.

WARNING: “State Street Corp Acquires 399,160 Shares of Akebia Therapeutics, Inc. (AKBA)” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2017/11/24/state-street-corp-acquires-399160-shares-of-akebia-therapeutics-inc-akba.html.

In related news, SVP Michel Dahan sold 1,398 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $19.64, for a total value of $27,456.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders sold 7,586 shares of company stock valued at $147,289. 7.95% of the stock is owned by corporate insiders.

Shares of Akebia Therapeutics, Inc. (NASDAQ AKBA) opened at $15.67 on Friday. Akebia Therapeutics, Inc. has a 1 year low of $7.78 and a 1 year high of $20.25.

Akebia Therapeutics (NASDAQ:AKBA) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.56) by $0.07. The business had revenue of $41.28 million during the quarter, compared to analysts’ expectations of $34.00 million. Akebia Therapeutics had a negative net margin of 137.80% and a negative return on equity of 198.85%. equities research analysts predict that Akebia Therapeutics, Inc. will post -2.25 earnings per share for the current year.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Want to see what other hedge funds are holding AKBA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Akebia Therapeutics, Inc. (NASDAQ:AKBA).

Institutional Ownership by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Stock Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related stocks with our FREE daily email newsletter.